Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
AstraZeneca
AZN
|
+$810M |
| 2 |
Intuitive Surgical
ISRG
|
+$705M |
| 3 |
S&P Global
SPGI
|
+$439M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
+$361M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$253M |
Top Sells
| 1 |
Broadcom
AVGO
|
+$605M |
| 2 |
FedEx
FDX
|
+$587M |
| 3 |
Monster Beverage
MNST
|
+$395M |
| 4 |
McDonald's
MCD
|
+$387M |
| 5 |
Booking.com
BKNG
|
+$380M |
Sector Composition
| 1 | Technology | 22.3% |
| 2 | Consumer Discretionary | 16.25% |
| 3 | Healthcare | 15.51% |
| 4 | Financials | 12.99% |
| 5 | Communication Services | 11.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
WBT
451
DELISTED
Welbilt, Inc.
WBT
| $12.1M | 0.01% |
579,878
+549,255
| +1,794% | +$11.5M |
|
|
NFX
452
DELISTED
Newfield Exploration
NFX
| $12M | 0.01% |
416,957
+18,137
| +5% | +$523K |
|
|
EVBG
453
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $11.9M | 0.01% |
205,627
+1,605
| +0.8% | +$92.5K |
|
|
AIMT
454
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $11.8M | 0.01% |
432,976
+3,442
| +0.8% | +$93.9K |
|
|
ANDX
455
DELISTED
Andeavor Logistics LP
ANDX
| $11.8M | 0.01% |
242,866
+9,348
| +4% | +$454K |
|
456
AT&T
T
$209B
| $11.7M | 0.01% |
460,085
-33
| -0% | -$837 |
|
457
Repligen
RGEN
$6.76B
| $11.6M | 0.01% |
208,690
+1,886
| +0.9% | +$105K |
|
458
Chemours
CC
$2.44B
| $11.6M | 0.01% |
292,943
-41,236
| -12% | -$1.63M |
|
|
RUBY
459
DELISTED
Rubius Therapeutics, Inc
RUBY
| $11.3M | 0.01% |
+472,209
| New | +$11.3M |
|
460
Dorman Products
DORM
$4.86B
| $11.1M | 0.01% |
144,575
+137,118
| +1,839% | +$10.5M |
|
|
IMGN
461
DELISTED
Immunogen Inc
IMGN
| $11.1M | 0.01% |
1,173,360
+8,717
| +0.7% | +$82.6K |
|
462
iRhythm Technologies
IRTC
$5.85B
| $10.8M | 0.01% |
114,451
-2,848
| -2% | -$270K |
|
|
CIM
463
Chimera Investment
CIM
$1.17B
| $10.8M | 0.01% |
198,143
-3,289
| -2% | -$179K |
|
464
Western Midstream Partners
WES
$14.6B
| $10.7M | 0.01% |
358,533
-125,410
| -26% | -$3.75M |
|
465
Sunrun
RUN
$3.74B
| $10.6M | 0.01% |
854,041
-56,801
| -6% | -$707K |
|
466
Apellis Pharmaceuticals
APLS
$3.29B
| $10.2M | 0.01% |
574,859
+4,395
| +0.8% | +$78.1K |
|
467
Charter Communications
CHTR
$35.9B
| $10.1M | 0.01% |
30,947
-243,567
| -89% | -$79.4M |
|
|
SEI
468
Solaris Energy Infrastructure, Inc.
SEI
$1.31B
| $9.99M | 0.01% |
528,745
-54,343
| -9% | -$1.03M |
|
469
AnaptysBio
ANAB
$637M
| $9.84M | 0.01% |
+98,593
| New | +$9.84M |
|
470
Philips
PHG
$26.9B
| $9.8M | 0.01% |
267,553
-122,303
| -31% | -$4.48M |
|
471
Keurig Dr Pepper
KDP
$37.3B
| $9.52M | 0.01% |
410,856
-179,685
| -30% | -$4.16M |
|
472
Viking Therapeutics
VKTX
$2.91B
| $9.5M | 0.01% |
+545,400
| New | +$9.5M |
|
473
Clearway Energy Class A
CWEN.A
$3.18B
| $9.49M | 0.01% |
498,335
-8,271
| -2% | -$157K |
|
474
NCS Multistage Holdings
NCSM
$131M
| $9.41M | 0.01% |
28,486
+6
| +0% | +$1.98K |
|
|
NBLX
475
DELISTED
Noble Midstream Partners LP
NBLX
| $9.24M | 0.01% |
260,895
-27,270
| -9% | -$966K |
|